C. McEwen
3 Papers
C. McEwen is an academic researcher. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Morbidity and mortality in patients managed with high compared with low blood pressure targets during on-pump cardiac surgery: a systematic review and meta-analysis of randomized controlled trials
C. McEwen,Takhliq Amir,Yuan Qiu,Jack Young,Kevin Kennedy,Hilary P. Grocott,Hessam H. Kashani,David Mazer,Scott Brudney,Morvarid S. Kavosh,Eric Jacobsohn,Anne G. Vedel,E. Wang,Richard P. Whitlock,Emilie P. Belley-Côté,Jessica Spence +15 more
- 10 Jan 2022
TL;DR: In this paper , the authors conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the impact of high compared with low intraoperative blood pressure targets on postoperative morbidity and mortality in adults undergoing cardiac surgery on cardiopulmonary bypass (CPB).
Correction to: Morbidity and mortality in patients managed with high compared with low blood pressure targets during on-pump cardiac surgery: a systematic review and meta-analysis of randomized controlled trials
C. McEwen,Takhliq Amir,Yuan Qiu,Jack Young,Kevin F. Kennedy,Hilary P. Grocott,Hessam H. Kashani,David Mazer,Scott Brudney,Morvarid S. Kavosh,Eric Jacobsohn,Anne G. Vedel,E. Wang,Richard P. Whitlock,Emilie P. Belley-Côté,Jessica Spence +15 more
- 14 Feb 2022
TL;DR: The mortality in patients managed with high compared with low blood pressure targets during onpump cardiac surgery and a systematic review and meta-analysis of randomized controlled trials are compared.
Anticoagulation for mechanical aortic valves: An international survey of current practice patterns and perceptions
Saurabh Gupta,C. McEwen,Winston Hou,Mark Crowther,D. Siegal,John Eikelboom,Richard P Whitlock,Emilie P. Belley-Côté +7 more
TL;DR: An international survey of cardiologists and specialists found varying INR targets for mechanical aortic valve patients, with 80% targeting 2.5 for low-risk patients and 44% targeting 3.0 for high-risk patients, despite perceived low-quality evidence supporting guidelines.